Neutropenia with fatal outcome in a multiple sclerosis patient 23 days after alemtuzumab infusion
Author:
Publisher
Elsevier BV
Subject
Neurology (clinical),Neurology,General Medicine
Reference5 articles.
1. Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment;Baker;Mult. Scler. Relat. Disord,2017
2. et al: CARE-MS II and CAMMS03409 Investigators. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings;Coles;Neurology,2017
3. Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis;Guarnera;Ther. Clin. Risk Manag.,2017
4. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab;Gaitán;JAMA Neurol.,2017
5. Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia;Österborg;Leukemia,2009
Cited by 21 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Disease-modifying therapies and hematological disorders: a systematic review of case reports and case series;Frontiers in Neurology;2024-06-18
2. Neutropenia following immune-depletion, notably CD20 targeting, therapies in multiple sclerosis;Multiple Sclerosis and Related Disorders;2024-02
3. RETRACTED: An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis;Pharmaceutics;2023-05-22
4. Prominent D‐dimer elevation and pretibial edema related to alemtuzumab treatment: A case report and literature review;Clinical and Experimental Neuroimmunology;2022-04-12
5. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so ‘pure’;Immunotherapy;2022-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3